Alex Hewitson is our Chief Operating Officer, where he has global oversight of our operations footprint and our human resources function. Prior to joining Alchemab, Alex held several senior leadership roles within AstraZeneca where he was most recently Head of Operations, ensuring business operations were maintained during the company’s transitional move to Cambridge, leading the […]

Paul Varley is our Chief Development Officer where he oversees our development processes including Pre-clinical Development, Toxicology, Chemistry Manufacturing and Control (CMC) and Quality. Prior to joining Alchemab, Paul held similar roles at Kymab, Ltd., AstraZeneca/MedImmune and Cambridge Antibody Technology. Paul also worked at British Biotech, the UK National Institute of Biological Standards and Control […]

Ralph Minter is our Chief Scientific Officer and leads our antibody discovery efforts. Prior to joining Alchemab, Ralph was Senior Director in Antibody Discovery and Protein Engineering at AstraZeneca where he led discovery teams and developed candidate drugs across multiple disease areas. Before joining AstraZeneca, he was part of Cambridge Antibody Technology (CAT), which later […]

Olivia Cavlan is Alchemab’s Chief Corporate Development and Strategy Officer where she oversees global business development and partnerships and leads corporate strategy. Prior to Alchemab Olivia was an Investment Principal at SV Health Investors and a Partner with McKinsey & Company where she was part of the leadership team in the Healthcare Private Equity and […]